The present Competitive Intelligence Report about Emerging Diabetes Drugs provides a competitor evaluation in the field of novel molecules against a series of novel targets being developed for treatment of type 1 or 2 diabetes as of April 2011. Pharmacologic approaches include SGLT inhibitors, glucokinase activators, 11beta-HSD1 inhibitors and many others. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. In addition, the report lists company-specific R&D pipelines of emerging diabetes drugs in R&D. Competitor projects are listed in a tabular format providing information on:

    * Drug Codes,
    * Target / Mechanism of Action,
    * Class of Compound,
    * Company,
    * Product Category,
    * Indication,
    * R&D Stage and
    * additional comments with a hyperlink leading to the source of information.

          o Sodium-Dependent Glucose Co-Transporter (SGLT) Inhibitors
          o 11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
          o Glucokinase Activators (GKA)
          o Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists
          o Sirtuin (SIRT) Activators
          o Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors
          o Glucagon Receptor (GCGR) Antagonists
          o Glucocorticoid Receptor (GCGR) Antagonists
          o Novel Insulin Sensitizers
          o G-Protein Coupled Receptor 119 (GPR119) Agonists
          o Other Drugs Augmenting GLP-1 Secretion: GPR40, GR120 & TGR5 Agonists
          o Other Glucometabolic Approaches
          o Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors
          o Other Metabolic Approaches
          o FGF-21-Receptor Agonists
          o Anti-Inflammatory Approaches
          o Induction of Immune Tolerance
          o Pancreatic Beta Cell Protection & Regeneration
          o Pancreatic Islet Cell Transplantation
          o Various Antidiabetic Approaches
      Corporate Emerging Diabetes Drugs R&D Pipelines
          o 7TM Pharma
          o Abbott
          o AdiStem
          o Advinus Therapeutics
          o Alize Pharma
          o ALLOZYNE
          o Ambrx
          o Amgen
          o Amylin Pharmaceuticals
          o Andromeda
          o Arena Pharmaceuticals
          o Array BioPharma
          o Astellas Pharma
          o AstraZeneca
          o Bayhill Therapeutics
          o Betagenon
          o BHV Pharma
          o Biocon
          o Boehringer Ingelheim
          o Bristol-Myers Squibb (BMS)
          o Catabasis Pharmaceuticals
          o Cellonis Biotechnologies
          o ChemoCentryx
          o Columbia University Medical Center
          o Connexios Life Sciences
          o Cortendo
          o CureDM Group
          o Cyclacel
          o Cytos Biotechnology
          o Daiichi Sankyo
          o Dainippon Sumitomo Pharma
          o Debiopharm
          o DiaKine Therapeutics
          o Diamedica
          o Diamyd Medical
          o Eli Lilly
          o Ensemble Discovery
          o Evotec
          o Exsulin
          o Forest Laboratories
          o Genzyme
          o Geron Corp
          o GlaxoSmithKline (GSK)
          o Helsinn
          o High Point Pharmaceuticals
          o Immunocore
          o Incyte
          o Inovio
          o Intercept Pharmaceuticals
          o Ipsen
          o ISIS Pharmaceuticals
          o Japan Tobacco
          o Johnson & Johnson (J&J)
          o Kalypsys
          o Karo Bio
          o Kotobuki
          o Les Laboratoires Servier (Servier)
          o Lexicon Pharmaceuticals
          o LG Life Science
          o Ligand Pharmaceuticals
          o Living Cell Technologies (LCT)
          o MacroGenics
          o MedImmune
          o Melior Discovery
          o Mesoblast
          o Metabolex
          o Merck & Co.
          o Mercury Therapeutics
          o MicroIslet
          o Mitsubishi Tanabe Pharma
          o Neurocrine Biosciences
          o National Institutes of Health (NIH)
          o Novartis
          o NovImmune
          o Omni Bio Pharmaceutical
          o Ortho-McNeil-Janssen Pharmaceuticals (OMJPI)
          o Ortho McNeil (J&J)
          o Osiris therapeutics
          o Pfizer
          o PharmaFrontier
          o Pinnacle
          o Piramal Life Sciences
          o Poxel
          o Rigel Pharmaceuticals
          o Roche
          o Sanofi-Aventis
          o S2 Therapeutics
          o Santarus
          o Sanwa Kagaku Kenkyusho
          o Sirona Biochem
          o Takeda Pharmaceutical
          o Targacept
          o Teva Pharmacetical Industries
          o Theracos
          o Tolera Therapeutics
          o Tolerx
          o TransTech Pharma
          o VeroScience
          o Versartis
          o VIA Pharmaceuticals
          o ViaCyte
          o Vitae Pharmaceuticals
          o Wellstat Therapeutics
          o XOMA
          o Yuhan Co.
          o Zydus Cadila
          o Yuhan

Pharmaceutical Market Research

Competitor Analysis: Emerging Diabetes Drugs

Competitor Analysis: Emerging Diabetes Drugs

Contents

Related products